RT info:eu-repo/semantics/article
T1 Impact of innovative treatment using biological drugs for the modulation of diffuse cutaneous systemic sclerosis: A systematic review
A1 Fernández Lázaro, Diego
A1 Iglesias Lázaro, María
A1 Garrosa, Evelina
A1 Rodríguez García, Saray
A1 Jerves Donoso, David
A1 Gutiérrez Abejón, Eduardo
A1 Jorge Finnigan, Conrado
K1 Scleroderma (Disease)
K1 Esclerodermia (Enfermedad)
K1 Autoimmune diseases
K1 Enfermedades autoinmunes
K1 Skin - Diseases
K1 Piel - Enfermedades
K1 Systemic scleroderma
K1 Immunology
K1 Dermatology
K1 Rheumatology
K1 Respiratory organs - Diseases
K1 Pulmonary function tests
K1 Lungs - Diseases
K1 Organos respiratorios - Enfermedades
K1 Pulmones - Enfermedades
K1 Health status indicators
K1 Biological products - Therapeutic use
K1 Drugs - Therapeutic use
K1 Medicamentos - Uso
K1 Public health
K1 2412 Inmunología
K1 3201.06 Dermatología
K1 3205.09 Reumatología
K1 3205.08 Enfermedades Pulmonares
K1 3212 Salud Publica
AB Scleroderma or systemic sclerosis (SSc) is an autoimmune disease affecting the connective tissue, characterized by fibrosis of the skin and internal organs. There is currently no curative treatment available, so therapeutic action is aimed at a symptomatic treatment of the affected organs. The development of biotechnology has made it possible to implement certain biological drugs that could represent a window of opportunity to modulate the evolution and symptomatology of scleroderma with greater efficacy and less toxicity than conventional treatments. This study aimed to review the current evidence critically and systematically on the effects of biological drugs on the pulmonary function, skin disease, and health status of patients afflicted by diffuse cutaneous systemic sclerosis (dcSSc). Three electronic databases (Pubmed, Dialnet, and Cochrane Library Plus) were systematically searched until the cut-off date of October 2022. The review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and included original articles in English and Spanish with a controlled trial design, comparing biological drug treatments (tocilizumab, belimumab, riociguat, abatacept, and romilkimab) with a control group. The methodological quality of the studies was assessed using the McMaster quantitative form and the PEDro scale. A total of 383 studies were identified, 6 of them met the established criteria and were included in the present systematic review. A total of 426 patients treated with tocilizumab, belimumab, riociguat, abatacept, and romilkimab were included. The results showed substantial non-significant (p < 0.05) improvement trends after treatment with the biological drugs included in this review for the modified Rodnan Scale Value, Forced Vital Capacity, and Carbon Monoxide Diffusion Test; however, no benefits were shown on the Health Assessment Questionnaire–Disability Index when compared to the control group. Biological drugs, therefore, maybe a new therapeutic strategy for dcSSc and could be recommended as an additional and/or adjunctive treatment that promotes anti-fibrotic activity. This review could further define the clinical rationale for the use of biologics in the treatment of dcSSc and could provide key details on the study protocol, design, and outcome reporting.
SN 1648-9144
YR 2023
FD 2023
LK https://uvadoc.uva.es/handle/10324/63443
UL https://uvadoc.uva.es/handle/10324/63443
LA eng
NO Medicina, 2023, Vol. 59, Nº. 2, 247
NO Producción Científica
DS UVaDOC
RD 13-may-2024